IgGκ Signal Peptide Enhances the Efficacy of an Influenza Vector Vaccine against Respiratory Syncytial Virus Infection in Mice.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
14 Jul 2023
Historique:
received: 15 06 2023
revised: 11 07 2023
accepted: 12 07 2023
medline: 31 7 2023
pubmed: 29 7 2023
entrez: 29 7 2023
Statut: epublish

Résumé

Intranasal vaccination using influenza vectors is a promising approach to developing vaccines against respiratory pathogens due to the activation of the mucosa-associated immune response. However, there is no clear evidence of a vector design that could be considered preferable. To find the optimal structure of an influenza vector with a modified NS genomic segment, we constructed four vector expressing identical transgene sequences inherited from the F protein of the respiratory syncytial virus (RSV). Two vectors were designed aiming at transgene accumulation in the cytosol. Another two were supplemented with an IgGκ signal peptide prior to the transgene for its extracellular delivery. Surprisingly, adding the IgGκ substantially enhanced the T-cell immune response to the CD8 epitope of the transgene. Moreover, this strategy allowed us to obtain a better protection of mice from the RSV challenge after a single intranasal immunization. Protection was achieved without antibodies, mediated by a balanced T-cell immune response including the formation of the RSV specific effector CD8+ IFNγ+/IL10+-producing cells and the accumulation of Treg cells preventing immunopathology in the lungs of infected mice. In addition to the presented method for optimizing the influenza vector, our results highlight the possibility of achieving protection against RSV through a respiratory-associated T-cell immune response alone.

Identifiants

pubmed: 37511205
pii: ijms241411445
doi: 10.3390/ijms241411445
pmc: PMC10380829
pii:
doi:

Substances chimiques

Influenza Vaccines 0
Antibodies, Viral 0
Respiratory Syncytial Virus Vaccines 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Federal State Budgetary Institution "Centre for Strategic Planning and Manage-ment of Biomedical Health Risks" of the Ministry of Health of the Russian Fed-eration
ID : 0373100122119000065

Références

Trends Biochem Sci. 2006 Oct;31(10):563-71
pubmed: 16919958
Eur J Immunol. 2015 Mar;45(3):780-93
pubmed: 25430701
J Gen Virol. 2008 Sep;89(Pt 9):2194-2203
pubmed: 18753229
Viral Immunol. 2008 Dec;21(4):483-9
pubmed: 19115938
Mucosal Immunol. 2018 Jan;11(1):249-256
pubmed: 28537249
Infect Immun. 1984 Feb;43(2):649-55
pubmed: 6693171
Clin Vaccine Immunol. 2006 Aug;13(8):898-904
pubmed: 16893990
Antiviral Res. 2015 Mar;115:1-8
pubmed: 25513755
J Virol. 2004 Dec;78(23):13037-45
pubmed: 15542655
Virol J. 2014 Apr 10;11:69
pubmed: 24716528
J Virol. 2006 Dec;80(23):11621-7
pubmed: 16971432
Proc Natl Acad Sci U S A. 2000 May 23;97(11):6108-13
pubmed: 10801978
Eur J Immunol. 2002 Aug;32(8):2117-23
pubmed: 12209623
Proc Natl Acad Sci U S A. 2020 Aug 11;117(32):19399-19407
pubmed: 32719124
Immunohorizons. 2021 Feb 3;5(2):59-69
pubmed: 33536235
Proc Natl Acad Sci U S A. 2008 Dec 30;105(52):20822-7
pubmed: 19075247
J Immunol. 2016 Feb 15;196(4):1721-31
pubmed: 26792805
J Exp Med. 2002 Nov 18;196(10):1381-6
pubmed: 12438429
Antiviral Res. 2018 Sep;157:102-110
pubmed: 29990516
Cytokine. 2020 Sep;133:154481
pubmed: 30031680
J Virol. 2008 Mar;82(5):2196-207
pubmed: 18094193
J Virol. 1998 Feb;72(2):1469-81
pubmed: 9445050
Pediatr Infect Dis J. 2003 Feb;22(2 Suppl):S94-9
pubmed: 12671459
J Immunol. 2004 Sep 1;173(5):3408-17
pubmed: 15322205
PLoS Pathog. 2011 Aug;7(8):e1002173
pubmed: 21829368
J Virol. 2013 Mar;87(6):3314-23
pubmed: 23302879
Biomed Res Int. 2014;2014:904038
pubmed: 24949479
Clin Vaccine Immunol. 2011 Oct;18(10):1776-80
pubmed: 21832097
J Virol. 1998 Aug;72(8):6437-41
pubmed: 9658085
Immunol Cell Biol. 2012 Nov;90(10):978-82
pubmed: 22929180
Microorganisms. 2021 Mar 26;9(4):
pubmed: 33810549
Immunol Res. 2014 Aug;59(1-3):109-17
pubmed: 24838148
Lancet. 2010 May 1;375(9725):1545-55
pubmed: 20399493
PLoS One. 2012;7(2):e32371
pubmed: 22393401
J Virol. 2008 Apr;82(8):4115-24
pubmed: 18272579
Pediatr Res. 2015 Nov;78(5):483-91
pubmed: 26267154
Am J Epidemiol. 1969 Apr;89(4):422-34
pubmed: 4305198
Antiviral Res. 2019 Aug;168:9-17
pubmed: 31075351
Mucosal Immunol. 2017 Mar;10(2):545-554
pubmed: 27220815
Vaccine. 2013 Dec 16;31(52):6239-46
pubmed: 24144478
Antiviral Res. 2020 Oct;182:104864
pubmed: 32585323
Front Immunol. 2015 Jun 05;6:298
pubmed: 26097483
N Engl J Med. 2005 Apr 28;352(17):1749-59
pubmed: 15858184
Immunity. 2019 Sep 17;51(3):429-442
pubmed: 31533056
PLoS One. 2015 Oct 15;10(10):e0139916
pubmed: 26468884
Lancet Glob Health. 2017 Oct;5(10):e984-e991
pubmed: 28911764
Clin Microbiol Rev. 2017 Jan;30(1):277-319
pubmed: 27903593
J Virol. 2005 Jun;79(11):6674-9
pubmed: 15890905
EMBO J. 2011 Apr 20;30(8):1634-44
pubmed: 21378750
PLoS Pathog. 2018 Jan 2;14(1):e1006810
pubmed: 29293660
J Clin Invest. 1991 Sep;88(3):1026-33
pubmed: 1909350
PLoS Pathog. 2015 Mar 13;11(3):e1004757
pubmed: 25769044
Hum Vaccin Immunother. 2018;14(12):2964-2970
pubmed: 30024831
Am J Respir Crit Care Med. 2015 May 1;191(9):1040-9
pubmed: 25730467
Tuberculosis (Edinb). 2006 May-Jul;86(3-4):236-46
pubmed: 16677861
Vaccine. 2018 May 11;36(20):2799-2808
pubmed: 29657070
N Engl J Med. 1986 Jul 10;315(2):77-81
pubmed: 3724802
Vaccine. 2014 May 23;32(25):2972-9
pubmed: 24726244

Auteurs

Anastasia Pulkina (A)

Smorodintsev Research Institute of Influenza of the Ministry of Health of the Russian Federation, 197022 St. Petersburg, Russia.

Kirill Vasilyev (K)

Smorodintsev Research Institute of Influenza of the Ministry of Health of the Russian Federation, 197022 St. Petersburg, Russia.

Arman Muzhikyan (A)

Smorodintsev Research Institute of Influenza of the Ministry of Health of the Russian Federation, 197022 St. Petersburg, Russia.

Mariia Sergeeva (M)

Smorodintsev Research Institute of Influenza of the Ministry of Health of the Russian Federation, 197022 St. Petersburg, Russia.

Ekaterina Romanovskaya-Romanko (E)

Smorodintsev Research Institute of Influenza of the Ministry of Health of the Russian Federation, 197022 St. Petersburg, Russia.

Anna-Polina Shurygina (AP)

Smorodintsev Research Institute of Influenza of the Ministry of Health of the Russian Federation, 197022 St. Petersburg, Russia.

Marina Shuklina (M)

Smorodintsev Research Institute of Influenza of the Ministry of Health of the Russian Federation, 197022 St. Petersburg, Russia.

Andrey Vasin (A)

Smorodintsev Research Institute of Influenza of the Ministry of Health of the Russian Federation, 197022 St. Petersburg, Russia.

Marina Stukova (M)

Smorodintsev Research Institute of Influenza of the Ministry of Health of the Russian Federation, 197022 St. Petersburg, Russia.

Andrej Egorov (A)

Smorodintsev Research Institute of Influenza of the Ministry of Health of the Russian Federation, 197022 St. Petersburg, Russia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH